[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344811-105":59,"doc-detail-344811-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trim59-tripartite-motif-containing-59-expression-in-pan-cancer-and-its-diagnostic-and-prognostic-implications-in-breast-cancer-esophageal-cancer-lung-squamous-cell-carcinoma-and-stomach-adenocarcinoma","TRIM59 (Tripartite Motif-Containing 59) Expression in Pan-Cancer and Its Diagnostic and Prognostic Implications in Breast Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, and Stomach Adenocarcinoma","","TRIM59 is investigated as a potential oncogene across pan-cancer, focusing on its links to tumor development, clinical features, and immune infiltration. Public datasets and multiple bioinformatics tools are used to evaluate expression patterns, protein-protein interactions, pathway enrichment, and diagnostic capability via ROC analyses. Prognostic relevance is assessed with survival analyses, including associations with immune cell infiltration and genetic alterations. Results highlight upregulation in multiple cancers and biomarker potential in selected breast, esophageal, lung, and stomach cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trim59-tripartite-motif-containing-59-expression-in-pan-cancer-and-its-diagnostic-and-prognostic-implications-in-breast-cancer-esophageal-cancer-lung-squamous-cell-carcinoma-and-stomach-adenocarcinoma/344811/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trim59-tripartite-motif-containing-59-expression-in-pan-cancer-and-its-diagnostic-and-prognostic-implications-in-breast-cancer-esophageal-cancer-lung-squamous-cell-carcinoma-and-stomach-adenocarcinoma/344811.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of this study on TRIM59?","Question",{"text":112,"@type":113},"To examine TRIM59 expression across pan-cancer and determine its diagnostic and prognostic implications, including links to tumorigenesis, clinicopathological factors, and immune cell infiltration.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cancers showed significant TRIM59 upregulation?",{"text":117,"@type":113},"TRIM59 was significantly upregulated in 22 cancers, with the highest expression reported in breast cancer, esophageal cancer, lung squamous cell carcinoma, and stomach adenocarcinoma.",{"name":119,"@type":110,"acceptedAnswer":120},"How did TRIM59 expression relate to patient outcomes and immune infiltration?",{"text":121,"@type":113},"High TRIM59 expression was associated with worse prognosis in kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, and lung adenocarcinoma, and it correlated with infiltration of multiple immune cell types across several cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344811,1790178145,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Review began 12/20/2025  \nReview ended 01/03/2026  \nPublished 01/17/2026  \n© Copyright 2026  \nAttaelmanan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CCBY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.101752  \nOpen Access Original Article  \nTRIM59 (Tripartite Motif-Containing 59) Expression in Pan-Cancer and Its Diagnostic and Prognostic Implications in Breast Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, and Stomach Adenocarcinoma  \nGamila A. Attaelmanan 1, Mohamed Y. Fateh Alrhman 2, Dina N. Abdelrahman 3, Tarteel Mohamed Mohanad Elkhidir 5, Roaa R. Mohamed 6, Howaida Hamad 7, Marwa Mohamed 8, Elaf Siddig 9, Mawada Muzzammil 10, Mohamed Alfaki 11  \n4  \n,  \n1. Medical Laboratory Sciences/Hematology, Al Neelain University, Khartoum, SDN 2. Faculty of Medicine, National Ribat University, Khartoum, SDN 3. Microbiology, Central Laboratory, Khartoum, SDN 4. Community Medicine, Hamad Medical Corporation, Doha, QAT 5. Faculty of Medicine, National University Biomedical Research Institute, Khartoum, SDN 6. Faculty of Medicine, Ahfad University for Women, Khartoum, SDN 7. Molecular Biology, Al Neelain University, Khartoum, SDN 8. Faculty of Pharmacy, University of Khartoum, Khartoum, SDN 9. Faculty of Pharmacy, University of Gezira, Khartoum, SDN 10. Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, SDN 11. Computer Science, Al Neelain University, Khartoum, SDN  \nCorresponding author: Mohamed Y. Fateh Alrhman, [yasermohammed73@gmail.com](yasermohammed73@gmail.com)  \nAbstract  \nBackground  \nCancers remain a significant global health challenge; identification of cutting-edge diagnostic and prognostic markers plus innovative therapeutic targets is crucial. Tripartite motif molecule 59 (TRIM59) is a potential oncogene. However, its specific role in cancers is lacking. We aimed to investigate the expression of TRIM59 in pan-cancer as well as its implications for tumorigenesis, clinicopathological factors, and immune cell infiltration. Moreover, we aimed to investigate the protein-protein interaction and evaluate its potential as a diagnostic and prognostic biomarker in pan-cancer using bioinformatic analysis.  \nMethods  \nWe analyzed TRIM59 across different cancer types using public datasets and bioinformatics tools. To study gene expression patterns, we used gene expression profiling interactive analysis (GEPIA), University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), tumor immune estimation resource (TIMER), and University of California, Santa Cruz (UCSC) Xena, and validated our findings using additional datasets from the Gene Expression Omnibus (GEO) datasets. We assessed diagnostic performance with receiver operating characteristic (ROC) curve analysis. We also used Kaplan-Meier plotter (K-M plotter), GEPIA, UALCAN, and TIMER to explore how TRIM59 expression relates to patient prognosis and immune cell infiltration. Genetic changes were examined with cBioPortal, while the search tool for recurring instances of neighboring genes (STRING) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis helped us study protein-protein interaction networks and pathway enrichment. For statistical analysis, we used the Limma (Linear Models for Microarray Analysis) program and standard tests.  \nResults  \nTRIM59 was significantly upregulated in 22 cancers, with the highest level of expression in breast cancer (BRCA), esophageal cancer (ESCA), lung squamous cell carcinoma (LUSC), and stomach adenocarcinoma (STAD) . High TRIM59 expression is significantly associated with a worse prognosis in kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD), and it was also associated with various clinicopathological factors in BRCA, ESCA, LUSC, STAD, and immune markers ","cbCaigwuqGmGVNEj","https://ap.wps.com/l/cbCaigwuqGmGVNEj","pdf",11019093,24,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main objective of this study on TRIM59?\",\"answer\":\"To examine TRIM59 expression across pan-cancer and determine its diagnostic and prognostic implications, including links to tumorigenesis, clinicopathological factors, and immune cell infiltration.\"},{\"question\":\"Which cancers showed significant TRIM59 upregulation?\",\"answer\":\"TRIM59 was significantly upregulated in 22 cancers, with the highest expression reported in breast cancer, esophageal cancer, lung squamous cell carcinoma, and stomach adenocarcinoma.\"},{\"question\":\"How did TRIM59 expression relate to patient outcomes and immune infiltration?\",\"answer\":\"High TRIM59 expression was associated with worse prognosis in kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, and lung adenocarcinoma, and it correlated with infiltration of multiple immune cell types across several cancers.\"}]","TRIM59 (Tripartite Motif-Containing 59) Expression in Pan-Cancer and Its Diagnostic and Prognostic Implications in Breast Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, and Stomach Adenocarcinoma | PDF",1790055341,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da226c8a747b48facf7ac40644a5e559.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff71af48aee4eec304ad6f585b91d206.webp",982,1389,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64dc050970c6508a3d20e11f7ffb4265.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ffd3df2b9bb98ff95ce41a677993088.webp",980,1386]